Efficacy of oral treprostinil as an add-on therapy for PAH
D. Kiely (Sheffield, United Kingdom), E. Grünig (Heidelberg, Germany), V. Balasubramanian (Fresno, United States), J. Barberà (Barcelona, Spain), C. Vizza (Rome, Italy), J. Elwing (Cincinnati, United States), N. Sood (Davis, United States), Y. Rao (Research Triangle Park, United States), L. Holdstock (Research Triangle Park, United States), S. Seaman (Research Triangle Park, United States), M. Broderick (Research Triangle Park, United States), R. White (Rochester, United States)
Source: International Congress 2022 – Treatment of pulmonary arterial hypertension
Session: Treatment of pulmonary arterial hypertension
Session type: Thematic Poster
Number: 2682
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Kiely (Sheffield, United Kingdom), E. Grünig (Heidelberg, Germany), V. Balasubramanian (Fresno, United States), J. Barberà (Barcelona, Spain), C. Vizza (Rome, Italy), J. Elwing (Cincinnati, United States), N. Sood (Davis, United States), Y. Rao (Research Triangle Park, United States), L. Holdstock (Research Triangle Park, United States), S. Seaman (Research Triangle Park, United States), M. Broderick (Research Triangle Park, United States), R. White (Rochester, United States). Efficacy of oral treprostinil as an add-on therapy for PAH. 2682
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|